Lung transplant airway complications treated with biodegradable airway stents: The Dutch multi‐center experience

Fuente: Wiley Open Access
Saved in:
Bibliographic Details
Main Authors: Roel van Pel, Tji Gan, Johannes M. A. Daniels, Dieuwertje Ruigrok, Merel E. Hellemons, Karin Klooster, Dirk‐Jan Slebos
Format: Artículo Open Access
Published: Wiley 2024
Subjects:
Online Access:
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1867004827090812928
author Roel van Pel
Tji Gan
Johannes M. A. Daniels
Dieuwertje Ruigrok
Merel E. Hellemons
Karin Klooster
Dirk‐Jan Slebos
author_facet Roel van Pel
Tji Gan
Johannes M. A. Daniels
Dieuwertje Ruigrok
Merel E. Hellemons
Karin Klooster
Dirk‐Jan Slebos
Roel van Pel
Tji Gan
Johannes M. A. Daniels
Dieuwertje Ruigrok
Merel E. Hellemons
Karin Klooster
Dirk‐Jan Slebos
collection Wiley Open Access
contents Lung transplant airway complications treated with biodegradable airway stents: The Dutch multi‐center experience Roel van Pel Tji Gan Johannes M. A. Daniels Dieuwertje Ruigrok Merel E. Hellemons Karin Klooster Dirk‐Jan Slebos Clinical Transplantation AbstractIntroductionTreatment of post lung‐transplant airway complications is challenging, and treatment with conventional airway stents is associated with adverse events. More recently, biodegradable airway stents (BDS) have been introduced and may be used to reduce these adverse events. In this study we explore the feasibility of treatment with BDS post lung transplant.MethodsAll patients treated with BDS in The Netherlands were included in this retrospective multicenter study. Feasibility, life span of the stent, occurrence of adverse events, and evolution of lung function were evaluated.ResultsTwelve patients (six malacia and six stenosis) received a total of 57 BDS, ranging from 1 to 10 BDS per patient. Six patients had been pretreated with conventional airway stents. Median stent life span was 112 days (range 66–202). No adverse events occurred during stent placement. In 5 out of 57 stent placements, a single additional bronchoscopy was necessary because of mucus accumulation (n = 4) or excessive granulation tissue (n = 1). All stent naïve patients became airway stent independent after treatment; all patients pretreated with conventional airway stents were still airway stent dependent at the end of follow up.ConclusionTreatment with BDS is safe and feasible. Adverse events were mild and easily treatable. All patients with initial treatment with BDS were airway stent independent at the end of follow up with a median treatment of 4 BDS. 10.1111/ctr.15289 http://creativecommons.org/licenses/by-nc-nd/4.0/
doi_str_mv 10.1111/ctr.15289
format Artículo Open Access
id wiley_oa_10_1111_ctr_15289
institution Wiley Open Access
license_str_mv http://creativecommons.org/licenses/by-nc-nd/4.0/
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Lung transplant airway complications treated with biodegradable airway stents: The Dutch multi‐center experience
Roel van Pel
Tji Gan
Johannes M. A. Daniels
Dieuwertje Ruigrok
Merel E. Hellemons
Karin Klooster
Dirk‐Jan Slebos
Clinical Transplantation
Lung transplant airway complications treated with biodegradable airway stents: The Dutch multi‐center experience Roel van Pel Tji Gan Johannes M. A. Daniels Dieuwertje Ruigrok Merel E. Hellemons Karin Klooster Dirk‐Jan Slebos Clinical Transplantation AbstractIntroductionTreatment of post lung‐transplant airway complications is challenging, and treatment with conventional airway stents is associated with adverse events. More recently, biodegradable airway stents (BDS) have been introduced and may be used to reduce these adverse events. In this study we explore the feasibility of treatment with BDS post lung transplant.MethodsAll patients treated with BDS in The Netherlands were included in this retrospective multicenter study. Feasibility, life span of the stent, occurrence of adverse events, and evolution of lung function were evaluated.ResultsTwelve patients (six malacia and six stenosis) received a total of 57 BDS, ranging from 1 to 10 BDS per patient. Six patients had been pretreated with conventional airway stents. Median stent life span was 112 days (range 66–202). No adverse events occurred during stent placement. In 5 out of 57 stent placements, a single additional bronchoscopy was necessary because of mucus accumulation (n = 4) or excessive granulation tissue (n = 1). All stent naïve patients became airway stent independent after treatment; all patients pretreated with conventional airway stents were still airway stent dependent at the end of follow up.ConclusionTreatment with BDS is safe and feasible. Adverse events were mild and easily treatable. All patients with initial treatment with BDS were airway stent independent at the end of follow up with a median treatment of 4 BDS. 10.1111/ctr.15289 http://creativecommons.org/licenses/by-nc-nd/4.0/
title Lung transplant airway complications treated with biodegradable airway stents: The Dutch multi‐center experience
topic Clinical Transplantation
url https://onlinelibrary.wiley.com/doi/10.1111/ctr.15289